Citi raised the firm’s price target on Merck (MRK) to $125 from $120 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- IHI, IHE, ARKG: Specialty Healthcare ETFs Offer Diversification and Growth to Investors
- Merck Animal Health’s Bravecto Quantum approved by FDA
- Trump Trade: President issues short-term waiver of Jones Act
- Trump claims TrumpRx website offers lowest prices, review says not so, NYT says
- Merck to present long-term efficacy of GARDASIL 9, GARDASIL at EUROGIN Congress